Leukemia
Leukemia is a heterogeneous group of malignant disorders characterized by the uncontrolled proliferation of abnormal hematopoietic cells within the bone marrow and peripheral blood. It arises due to genetic and epigenetic alterations that disrupt normal mechanisms of cell differentiation, proliferation, and apoptosis, leading to the accumulation of immature or dysfunctional white blood cells. The pathogenesis involves chromosomal translocations, gene mutations, and dysregulation of signaling pathways that drive leukemogenesis. These malignant cells suppress normal hematopoiesis, resulting in anemia, thrombocytopenia, and immunodeficiency. The health impacts of leukemia are profound, encompassing life-threatening cytopenias, increased susceptibility to infections, bleeding complications, and infiltration of extramedullary organs, which together contribute to significant morbidity and mortality if left untreated.
Acute Lymphoblastic Leukemia is a rapidly progressing malignancy arising from lymphoid progenitor cells, most commonly affecting children but also seen in adults. It is characterized by the proliferation of immature lymphoblasts in the bone marrow, peripheral blood, and sometimes extramedullary sites. ALL is subclassified based on immunophenotype (B-cell or T-cell lineage) and genetic abnormalities, which influence prognosis and therapeutic strategies. Clinical features include fatigue, fever, bleeding, bone pain, lymphadenopathy, and hepatosplenomegaly.
Acute Myeloid Leukemia is an aggressive hematological cancer resulting from the clonal expansion of myeloid precursor cells, leading to impaired differentiation and accumulation of blasts in the bone marrow and blood. AML predominantly affects adults but can occur at any age. Its etiology is multifactorial, involving environmental exposures, prior chemotherapy or radiation, and inherited predispositions. Patients typically present with symptoms of marrow failure, such as anemia, infections, and hemorrhage, as well as organ infiltration.
Chronic Lymphocytic Leukemia is a slowly progressing malignancy of mature B lymphocytes, primarily affecting older adults. It is characterized by the accumulation of small, functionally incompetent lymphocytes in the blood, bone marrow, lymph nodes, and spleen. CLL is often discovered incidentally during routine blood tests and can remain indolent for years. Clinical manifestations, when present, include lymphadenopathy, splenomegaly, recurrent infections, and, in advanced cases, cytopenias due to marrow infiltration.
Chronic Myeloid Leukemia is a myeloproliferative neoplasm defined by the presence of the Philadelphia chromosome, resulting from the BCR-ABL1 fusion gene. This genetic abnormality leads to constitutive tyrosine kinase activity, driving uncontrolled myeloid cell proliferation. CML typically follows a triphasic course: chronic, accelerated, and blast crisis phases. Patients may be asymptomatic or present with fatigue, weight loss, splenomegaly, and elevated white blood cell counts. Targeted therapies have significantly improved outcomes in CML.
Leukemia accounts for approximately 2.5% of all new cancer cases worldwide, with an estimated global incidence of over 474,000 cases and approximately 311,000 deaths annually. The disease exhibits significant heterogeneity by age, sex, and geographic region. Acute lymphoblastic leukemia is the most common cancer in children, representing about 25% of pediatric malignancies, whereas acute myeloid leukemia and chronic lymphocytic leukemia are more prevalent in adults, particularly in the elderly population. Chronic myeloid leukemia constitutes about 15% of adult leukemias. Incidence rates are generally higher in high-income countries, with variations attributed to genetic, environmental, and socioeconomic factors. Males are generally at a slightly higher risk than females. The overall five-year survival rate for leukemia varies by subtype, age, and access to advanced therapies, ranging from over 85% in pediatric ALL to less than 30% in older adults with AML.
The diagnosis of leukemia is established through a combination of clinical evaluation, laboratory investigations, and specialized diagnostic procedures. Initial assessment includes a thorough history and physical examination, focusing on symptoms of cytopenia, organomegaly, and lymphadenopathy. Laboratory evaluation typically reveals abnormalities in complete blood count, such as anemia, leukocytosis or leukopenia, and thrombocytopenia, with the presence of blasts on peripheral blood smear suggestive of acute leukemia. Definitive diagnosis requires bone marrow aspiration and biopsy, enabling morphological assessment and quantification of blast cells. Immunophenotyping by flow cytometry is essential to determine lineage and classify leukemia subtype. Cytogenetic and molecular analyses, including karyotyping, fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR), identify characteristic chromosomal translocations and gene mutations, which are crucial for risk stratification and treatment selection. Additional studies may include lumbar puncture for central nervous system involvement and imaging to assess extramedullary disease. Diagnostic criteria are based on the World Health Organization (WHO) classification, with specific thresholds for blast percentage and genetic findings.
Revumenib fumarate is utilized as a therapeutic agent in leukemia, acting as a selective inhibitor of the menin-KMT2A interaction to target leukemogenic gene expression. Pirtobrutinib, a non-covalent Bruton’s tyrosine kinase inhibitor, is employed to disrupt B-cell receptor signaling pathways in leukemic cells. Olutasidenib functions as an isocitrate dehydrogenase 1 (IDH1) inhibitor, providing targeted therapy for leukemia patients harboring IDH1 mutations. Asparaginase Erwinia chrysanthemi (recombinant) is an enzyme-based therapy that depletes asparagine, an amino acid essential for leukemic cell survival, especially in acute lymphoblastic leukemia. Orelabrutinib, another Bruton’s tyrosine kinase inhibitor, is administered to inhibit malignant B-cell proliferation. Rituximab and rituximab-arrx are monoclonal antibodies directed against the CD20 antigen on B lymphocytes, facilitating targeted destruction of leukemic B-cells. Asciminib hydrochloride is an allosteric inhibitor of BCR-ABL1, used in the management of Philadelphia chromosome-positive leukemias. Olverembatinib mesylate is a tyrosine kinase inhibitor that targets BCR-ABL1 and its resistant mutations, offering therapeutic benefit in refractory cases. Lisocabtagene maraleucel is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, engineered to recognize and eliminate malignant B-cells in certain leukemias.
| Structure | Generic Name | CAS Registry Number | Molecular Formula | Molecular Weight |
|---|---|---|---|---|
 | revumenib fumarate (Rec INNM) | 2 C32 H47 F N6 O4 S . 3 C4 H4 O4 | 1609.85 | |
 | pirtobrutinib (Rec INN; USAN) | 2101700-15-4 | C22 H21 F4 N5 O3 | 479.427 |
 | olutasidenib (Rec INN; USAN) | 1887014-12-1 | C18 H15 Cl N4 O2 | 354.79 |
| asparaginase Erwinia chrysanthemi (recombinant) (USAN); asparaginase erwinia chrysanthemi (recombinant)-rywn | 1349719-22-7 | |||
 | orelabrutinib (Rec INN; USAN) | 1655504-04-3 | C26 H25 N3 O3 | 427.495 |
| rituximab; rituximab-arrx | ||||
 | asciminib hydrochloride (Rec INNM; USAN) | 2119669-71-3 | C20 H18 Cl F2 N5 O3 . Cl H | 486.299 |
 | olverembatinib mesylate (Rec INNM; USAN) | 1257628-77-5 (free base) | C29 H27 F3 N6 O . 2 C H4 O3 S | 724.771 |
| lisocabtagene maraleucel (Rec INN; USAN) | 2099722-39-9 | |||
| rituximab |
Make Order
Experimental Scheme
Implementation
Conclusion
Solutions For Leukemia
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.